The Farnesoid X receptor - A molecular link between bile acid and lipid and glucose metabolism

被引:386
作者
Claudel, T
Staels, B
Kuipers, F
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Pediat Lab, Ctr Liver Digest & Metab Dis, NL-9700 RB Groningen, Netherlands
[2] Inst Pasteur, Dept Atherosclerose, INSERM, Unite Rech 545, F-59019 Lille, France
[3] Univ Lille 2, Fac Pharm, Lille, France
关键词
bile acid; FXR; glucose metabolism; lipid; nuclear receptor;
D O I
10.1161/01.ATV.0000178994.21828.a7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bile acids are the end products of cholesterol metabolism. They are synthesized in the liver and secreted via bile into the intestine, where they aid in the absorption of fat-soluble vitamins and dietary fat. Subsequently, bile acids return to the liver to complete their enterohepatic circulation. The Farnesoid X receptor (FXR) is a member of the nuclear receptor superfamily and has emerged as a key player in the control of multiple metabolic pathways. On its activation by bile acids, FXR regulates bile acid synthesis, conjugation, and transport, as well as various aspects of lipid and glucose metabolism. This review summarizes recent advances in deciphering the role of FXR in the context of hepatic lipid and glucose homeostasis and discusses the potential of FXR as a pharmacological target for therapeutic applications.
引用
收藏
页码:2020 / 2031
页数:12
相关论文
共 161 条
  • [1] AINSFELD AM, 2003, J BIOL CHEM, V26, P26
  • [2] Colesevelam hydrochloride: A novel bile acid-binding resin
    Aldridge, MA
    Ito, MK
    [J]. ANNALS OF PHARMACOTHERAPY, 2001, 35 (7-8) : 898 - 907
  • [3] Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor
    Ananthanarayanan, M
    Balasubramanian, N
    Makishima, M
    Mangelsdorf, DJ
    Suchy, FJ
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (31) : 28857 - 28865
  • [4] ALTERED BILE-ACID PROFILES IN DUODENAL BILE AND URINE IN DIABETIC SUBJECTS
    ANDERSEN, E
    KARLAGANIS, G
    SJOVALL, J
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1988, 18 (02) : 166 - 172
  • [5] CHOLESTEROL-BIOSYNTHESIS IN NONKETOTIC DIABETICS BEFORE AND DURING INSULIN THERAPY
    ANDERSEN, E
    HELLSTROM, P
    HELLSTROM, K
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 1987, 3 (04) : 207 - 214
  • [6] FXR induces the UGT2B4 enzyme in hepatocytes: A potential mechanism of negative feedback control of FXR activity
    Barbier, O
    Torra, IP
    Sirvent, A
    Claudel, T
    Blanquart, C
    Duran-Sandoval, D
    Kuipers, F
    Kosykh, V
    Fruchart, JC
    Staels, B
    [J]. GASTROENTEROLOGY, 2003, 124 (07) : 1926 - 1940
  • [7] BARNES S, 1989, J LIPID RES, V30, P529
  • [8] CHENODEOXYCHOLIC ACID THERAPY FOR HYPERTRIGLYCERIDEMIA IN MEN
    BATESON, MC
    MACLEAN, D
    EVANS, JR
    BOUCHIER, IAD
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1978, 5 (03) : 249 - 254
  • [9] DISORDERS OF BILE-ACID METABOLISM IN CHOLESTEROL GALLSTONE DISEASE
    BERR, F
    PRATSCHKE, E
    FISCHER, S
    PAUMGARTNER, G
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (03) : 859 - 868
  • [10] TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA - UNITED-KINGDOM LIPID CLINICS STUDY OF PRAVASTATIN AND CHOLESTYRAMINE
    BETTERIDGE, DJ
    BHATNAGER, D
    BING, RF
    DURRINGTON, PN
    EVANS, GR
    FLAX, H
    JAY, RH
    LEWISBARNED, NL
    MANN, J
    MATTHEWS, DR
    MILLER, JP
    RECKLESS, JPD
    STURLEY, R
    TAYLOR, KG
    WINDER, AF
    [J]. BRITISH MEDICAL JOURNAL, 1992, 304 (6838) : 1335 - 1338